Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

Completed · Early Phase 1

Conditions studied: Prostate Cancer

In brief

This is a pilot, non-randomized, two-cohort interventional study in patients who meet the inclusion criteria, using an FDA- approved androgen deprivation agent for a 3 or 6-week course of treatment prior to standard-of-care RALP with PLND. The intent of the study is to determine the effect of ADT on PSMA expression as measured by PSMA-PET scan. A second PSMA-PET scan will be performed after ADT for either 3 or 6 weeks, depending on cohort, prior to RALP and PLND.

Key facts

Study ID

NCT07069465

Run by

Urology Clinics of North Texas

People needed

10

Starts

2024-06-15

Expected to finish

2024-11-06

Last updated by the study team

2025-07-16

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men diagnosed with unfavorable intermediate or high-risk prostate cancer where RALP and PLND is planned and consulted with primary urologist

Where it is running

• Urology Clinics of North Texas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.